Evidence map›Paper›PMID 29462661›Full record

ArticleCellular signalling2018

p66Shc regulates migration of castration-resistant prostate cancer cells.

Matthew A Ingersoll, Yu-Wei Chou, Jamie S Lin, Ta-Chun Yuan, Dannah R Miller, Yan Xie, Yaping Tu, Rebecca E Oberley-Deegan, Surinder K Batra, Ming-Fong Lin

Abstract read
In one paragraph

Article in Cellular signalling, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Matthew A IngersollDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States.
Yu-Wei ChouDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States; Tissue Bank and BioBank, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan.
Jamie S LinDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States; Section of Nephrology, Division of Internal Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, United States.
Ta-Chun YuanDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States; Department of Life Science, National Dong Hwa University, Hualien 974, Taiwan.
Dannah R MillerDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States.
Yan XieDepartment of Pharmacology, Creighton University School of Medicine, Omaha, NE, United States.
Yaping TuDepartment of Pharmacology, Creighton University School of Medicine, Omaha, NE, United States.
Rebecca E Oberley-DeeganDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States.
Surinder K BatraDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, United States.
Ming-Fong LinDepartment of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, United States; Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, United States; Section of Urology, Department of Surgery, University of Nebraska Medical Center, Omaha, NE, United States; College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807, Taiwan. Electronic address: mlin@unmc.edu.
University of Nebraska Medical Center · USCreighton University · USNebraska Medical Center · USKaohsiung Chang Gung Memorial Hospital · TWNational Dong Hwa University · TWThe University of Texas MD Anderson Cancer Center · US

Funding

UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
CHEMICAL CARCINOGENESIS &CANCER BIOLOGYT32CA009476 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Jennifer D. Black · 1988 to 2026
$6.2M
Research Pilot Project ProgramP30GM106397 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI JOHNSON, KEITH R · 2013 to 2017
$4.9M
SIGNALING IN ANDROGEN REFRACTORY PROSTATE CANCERR01CA088184 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI LIN, MING-FONG · 2000 to 2010
$2.6M
MIC-1 and its functional partners in prostate cancer racial disparityU01CA185148 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BATRA, SURINDER K. · 2015 to 2019
$1.6M
NCI NIH HHS P30 CA036727NCI NIH HHS R01 CA088184NCI NIH HHS T32 CA009476NCI NIH HHS U01 CA185148NIGMS NIH HHS P30 GM106397
6 · The paper itself

Abstract

Metastatic castration-resistant (CR) prostate cancer (PCa) is a lethal disease for which no effective treatment is currently available. p66Shc is an oxidase previously shown to promote androgen-independent cell growth through generation of reactive oxygen species (ROS) and is elevated in clinical PCa and multiple CR PCa cell lines. We hypothesize p66Shc also increases the migratory activity of PCa cells through ROS and investigate the associated mechanism. Using the transwell assay, our study reveals that the level of p66Shc protein correlates with cell migratory ability across several PCa cell lines. Furthermore, we show hydrogen peroxide treatment induces migration of PCa cells that express low levels of p66Shc in a dose-dependent manner, while antioxidants inhibit migration. Conversely, PCa cells that express high levels of endogenous p66Shc or by cDNA transfection possess increased cell migration which is mitigated upon p66Shc shRNA transfection or expression of oxidase-deficient dominant-negative p66Shc W134F mutant. Protein microarray and immunoblot analyses reveal multiple proteins, including ErbB-2, AKT, mTOR, ERK, FOXM1, PYK2 and Rac1, are activated in p66Shc-elevated cells. Their involvement in PCa migration was examined using respective small-molecule inhibitors. The role of Rac1 was further validated using cDNA transfection and, significantly, p66Shc is found to promote lamellipodia formation through Rac1 activation. In summary, the results of our current studies clearly indicate p66Shc also regulates PCa cell migration through ROS-mediated activation of migration-associated proteins, notably Rac1.

Indexed as

AntioxidantsCell Line, TumorCell MovementHumansHydrogen PeroxideMaleProstatic Neoplasms, Castration-ResistantPseudopodiarac1 GTP-Binding ProteinReactive Oxygen SpeciesSignal TransductionSrc Homology 2 Domain-Containing, Transforming Protein 1AntioxidantsHydrogen Peroxiderac1 GTP-Binding ProteinRAC1 protein, humanReactive Oxygen SpeciesSHC1 protein, humanSrc Homology 2 Domain-Containing, Transforming Protein 1Castration-resistantCell migrationp66ShcProstate cancerRac1Reactive oxygen species

Identifiers

PMID29462661
PMCPMC5882563
OpenAlexW2789931394

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.